Sign in

Marcus Ruscetti Lab

@marcus-ruscetti.bsky.social
464 followers 735 following 46 posts

Ruscetti lab at UMass Chan Medical School. Defining and targeting tumor intrinsic drivers of immune evasion for cancer immunotherapy. #prostatecancer #pancreaticcancer

PostsRepliesMedia
Reposted by Marcus Ruscetti Lab
UMass Chan Medical School @umasschan.bsky.social · 12/08/2026
A potentially transformative mRNA immunotherapy developed at UMass Chan eliminated pancreatic cancer tumors in 50 percent of treated mice models. Read about the research, published in Nature Communications: bit.ly/3S01eiX #PancreaticCancer @marcus-ruscetti.bsky.social @uofmass.bsky.social
umassmed.edu
mRNA immunotherapy developed by UMass Chan scientists eliminates pancreatic tumors in mice
Novel mRNA treatment developed at UMass Chan Medical School eliminates pancreatic cancer tumors in 50 percent of treated mice.
131
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 31/07/2026
Our paper is out today at Nature Communications. Chaitanya Parikh in our lab developed an all-in-one cytokine and antigen mRNA therapy that can produce pancreatic cancer cures in 50% of mice! Excited to take this technology into patients with our company ImmunoScript. www.nature.com/articles/s41...
nature.com
Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer - Nature Communications
Pancreatic ductal adenocarcinoma (PDAC) displays dismal immunotherapy outcomes in part through a lack of cytokine and antigen signals needed for anti-tumor immunity. The authors here develop a cocktai...
040
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 30/03/2026
Link to research associate position: ummsjobs.com/job/11424/
ummsjobs.com
UMass Chan Medical School | ITM
000
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 30/03/2026
Link to postdoc position: talent.umassmed.edu/jobs/49528?l...
talent.umassmed.edu
Post Doc - Open Rank - Ruscetti Lab in Worcester, Massachusetts | University of Massachusetts Medical School
UMMS is hiring a Post Doc - Open Rank - Ruscetti Lab in Worcester, Massachusetts. Review all of the job details and apply today!
120
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 30/03/2026
Our lab is recruiting both a postdoc and research technician to start in May/June! If you know anyone interested in investigating mechanisms of metastasis and immune suppression in cancer through developing innovative mouse models and studying senescence, please spread the word! Links below.
130
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 20/12/2025
Thanks Bill!
000
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 18/12/2025
Unexpected news to end 2025. I have been promoted to Associate Professor @umasschan.bsky.social! Thanks to all the colleagues, mentors, and collaborators here and abroad who have contributed to my and the lab's development, as well as our amazing lab members who make doing science such a thrill!
140
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 07/11/2025
Thanks again for the invite! Had a blast and learned a ton. The future of senescence research is bright.
051
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
With her NIH F31 fellowship, Kat Murphy is now leveraging these models to explore the molecular and cellular determinants of immune suppression and immunotherapy failure in another aggressive and highly metastatic form of CRPC: neuroendocrine prostate cancer. Stay tuned for more to come!
000
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
Thanks to editor @harmonyturk.bsky.social at Cancer Research, who made the publishing process streamlined and timely, and to our Reviewers, who provided helpful comments and suggestions that improved the manuscript.
110
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
Given the number of bispecific antibodies targeting VEGFR2/PD-L1 currently on the market and in clinical trials, we believe that the 8-9% of CRPC patients harboring MYC and p53 genetic alterations could highly benefit from these immunotherapies as a “precision medicine” approach.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
Moreover, VEGFR2 blockade could potentiate anti-PD-L1 immune checkpoint blockade therapy that is generally ineffective in the broader prostate cancer patient population in our MYC and p53 altered CRPC models.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
Treatment with VEGFR2 blocking antibodies could reactivate cytotoxic anti-tumor T cell immunity to block prostate tumor growth and metastasis in this aggressive MYC and p53-driven genetic CRPC subtype.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
Mechanistically, MYC and p53 alterations cooperated to drive secretion of VEGF from prostate tumor cells. Though VEGF typically mediates vascular remodeling and angiogenesis, Kat found that VEGF could also directly reduce migration and activation of CD8+ T cells expressing its receptor, VEGFR2.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
She identified a genetic subtype of castration-resistant prostate cancer (CRPC) with MYC oncogene overexpression and p53 tumor suppressor deletion that had reduced NK and T cell infiltration and activity compared to other subtypes and an overall dismal prognosis in mice and men.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
Using an in vivo electroporation technique that allows for generation of any genetic alteration found in human cancers in mice, Kat produced a suite of prostate cancer mouse models with different oncogene and tumor suppressor alterations and analyzed their immune landscapes.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
What are the genetic determinants of immune suppression and immunotherapy resistance in cancer? In a recent study from our lab, Kat Murphy developed innovative genetically engineered mouse models of late-stage prostate cancer to address this question. aacrjournals.org/cancerres/ar...
aacrjournals.org
MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
AbstractPatients with castration-resistant prostate cancer (CRPC) are generally unresponsive to tumor-targeted treatments and immunotherapies. Genetic alterations acquired during the evolution of CRPC...
150
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 03/11/2025
Could not be more proud of Kat and all she has accomplished in graduate school and beyond! Be sure to also check out her recent paper in Cancer Research elucidating genetic mechanisms of immune suppression and immunotherapy resistance in prostate cancer. aacrjournals.org/cancerres/ar...
aacrjournals.org
MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
AbstractPatients with castration-resistant prostate cancer (CRPC) are generally unresponsive to tumor-targeted treatments and immunotherapies. Genetic alterations acquired during the evolution of CRPC...
060
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
The fabulous Lin Zhou, the 1st author who drove the study, is currently on the job market. She is following up on this work to investigate how p21+ stromal cells arise, how they are different from other senescent cells, and how to best target them in cancer. Snatch her up before someone else does!
010
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
As always, it was a real pleasure working with Michele Hartsough and the editorial team at Cancer Discovery. And thanks to our Reviewers for their helpful comments along the way that improved the manuscript.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
This was a great team effort from all authors, including my former Ph.D. mentor!
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
Our findings suggest that, in contrast to senescent transformed epithelial cells that are growth arrested and tumor suppressive, p21+ senescent stromal cells secrete a SASP that fuels immune suppression and tumor growth that can be targeted for therapeutic intervention and to enhance immunotherapy.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
Targeting p21+ senescent stromal cells genetically or through treatment with ABT-263 could also enhance anti-PD-1 immune checkpoint blockade therapy outcomes in advanced, castration-resistant prostate cancer models.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
Administration of the senolytic BCL-2 family inhibitor ABT-263 also preferentially targeted p21+ senescent stromal cells, leading to reactivation of anti-tumor T cell immunity that could even block prostate tumor initiation.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
Through a series of experiments to deplete p16+ or p21+ senescent cells in different cellular compartments in mice, we found that while p16 removal had no effect on tumor progression, p21+ stromal cell depletion could block SASP to reverse myeloid immune suppression and delay tumor growth.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
Whereas p16+ senescent epithelial cells had very low expression of inflammatory factors through the senescence-associated secretory phenotype (SASP), p21+ senescent stromal cells had high production of SASP cytokines that recruit suppressive myeloid cells.
110
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
To our surprise, single cell sequencing revealed that different populations of senescent cells expressed different senescent markers. While transformed senescent epithelial preferentially expressed p16, senescent cells in stromal populations expressed another putative senescence marker: p21.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
Using patient samples and mouse models of early prostate cancer development, we found that senescent cells accumulate in both the tumor and the surrounding non-tumor stroma throughout disease progression, where they were associated with T cell suppression.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 29/10/2025
How can senescent cells, which are damaged and growth arrested, both block tumor initiation as well as fuel its growth? A recent study published in Cancer Discovery @aacrjournals.bsky.social from Lin Zhou in the lab uncovered some new insights into this puzzle. aacrjournals.org/cancerdiscov...
aacrjournals.org
P21-positive senescent stromal cells promote prostate cancer immune suppression and progression that can be reversed by senolytic therapy
Abstract. Cellular senescence is a well-established tumor-suppressive cell cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternat...
1174
Reposted by Marcus Ruscetti Lab
Elizabeth McKenna @elizsmckenna.bsky.social · 28/10/2025
Now online in Cancer Discovery @aacrjournals.bsky.social: p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression & Progression that Can Be Reversed by Senolytic Therapy - by Lin Zhou, @marcus-ruscetti.bsky.social, and colleagues doi.org/10.1158/2159... @umasschan.bsky.social
093
Reposted by Marcus Ruscetti Lab
PitarresiLab @pitarresilab.bsky.social · 30/09/2025
Congrats to postdoc @nikitab.bsky.social for being awarded an AACR Scholar-in-Training award for this year's #AACRPan25 conference. Be sure to check out her poster # B049 today from 6-9pm!
0111
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
Forgot to tag @fitzgeraldkate.bsky.social! Great collaborating with you on this.
000
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
This was a team effort from members of our lab and a number of labs and colleagues with different expertise! Also very appreciative of the great feedback from our reviewers and assistance from editors and staff @pnas.org
010
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
Our study contributes a more generalizable approach to stabilize STING and increase immunogenicity in cold tumors where STING expression is silenced through targeting PPT1. We believe this could open the door for rationale combinations with STING agonists and ICB therapies.
120
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
Remarkably, analysis of patient datasets demonstrated that high PPT1 expression was associated with drastically reduced survival outcomes in cancer patients treated with immune checkpoint blockade therapies.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
Use of a PPT1 small molecule inhibitor in clinical development could induce STING expression in tumor cells in vivo, leading to reduced tumor growth and activating CD8+T cells in mouse models of prostate and ovarian cancers.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
Genetic or pharmacological inhibition of PPT1 could enhance STING protein expression and downstream signaling in tumor cells to induce production of cytokines important for anti-tumor immunity.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
Mechanistically, she found the PPT1 promoted the turnover and lysosomal degradation of STING, leading to attenuation of its downstream inflammatory signaling capacity that can drive immune responses in cancer.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
Shreya pulled out a number of negative regulators of STING expression from the screen, and focused on the palmitoyl-protein thioesterase PPT1, which she found to be overexpressed and amplified in human prostate and ovarian cancers with low STING levels.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
This project initially began in the lab of the late great Michael R. Green, with the idea of performing a CRISPR screen to identify novel, targetable regulators of STING in tumor cells that often silence STING expression and as such are not responsive to STING agonists.
100
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 23/09/2025
*NEW paper alert* In a recent study from our former postdoc Shreya Chowdhury and in collaboration with Kate Fitzgerald, we identified PPT1 as a negative regulator of STING in tumor cells whose targeting could reactivate T cell immunity in ovarian and prostate cancers. www.pnas.org/doi/10.1073/...
pnas.org
PNAS
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...
230
Reposted by Marcus Ruscetti Lab
Trudy G. Oliver @tgoliver.bsky.social · 17/09/2025
Super pleased to announce our latest suggesting the cell of origin for #SCLC is most likely the basal cell @nature.com, not the accepted neuroendocrine cell. Implications for the earliest events in cancer, & providing new models of tuft-like cancer. rdcu.be/eGUtj
rdcu.be
Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer
Nature - Basal cells, rather than neuroendocrine cells, have been identified as the probable origin of small cell lung cancer and other neuroendocrine–tuft cancers, explaining...
54712
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 22/09/2025
This month our lab is celebrating 5 years! Couldn't be more thrilled with and proud of the group we have. Great scientists and human beings all around. Also super excited about the science coming out of the lab. Stay tuned for a few new studies dropping in the upcoming weeks.
040
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 15/08/2025
Congrats @nikitab.bsky.social !
120
Reposted by Marcus Ruscetti Lab
Victor Ambros @vambros.bsky.social · 31/03/2025
www.nytimes.com/interactive/...
nytimes.com
Read the Letter
Researchers at academic institutions nationwide say that U.S. science is being dismantled.
44325
Reposted by Marcus Ruscetti Lab
Ardem Patapoutian @ardemp.bskyverified.social · 07/03/2025
Why do we even have to do this? I wondered the whole time at Stand for Science. 🧪 But it was inspiring to see so many people committed to fighting for truth, science, and justice!
618822
Reposted by Marcus Ruscetti Lab
Nuria Lopez-Bigas @nlbigas.bsky.social · 07/03/2025
#standupforscience Boston
0243
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 07/03/2025
Congrats to Haruka from the Atukorale and Ruscetti labs for passing her qualifying exam to become a Ph.D. candidate yesterday! We are proud mentors and can't wait to see what you can accomplish through engineering LNPs for drug delivery in pancreatic cancer!
020
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 07/01/2025
Original article here: www.cell.com/cell/fulltex...
cell.com
Identifying specific functional roles for senescence across cell types
A dual recombinase-mediated genetic system for cell-type-specific lineage tracing, ablation, and gene manipulation of senescent cells reveals distinct roles of senescence across cell types.
010
Marcus Ruscetti Lab @marcus-ruscetti.bsky.social · 07/01/2025
Happy to highlight work from Zhao et al., who developed 4! new mouse models to trace and genetically manipulate different p16+ senescent cell types that will be invaluable to the field. Check out my spotlight @Dev_Cell and original article in @cellcellpress.bsky.social www.cell.com/developmenta...
cell.com
Lineage tracing senescence in vivo shows not all senescent cells are created equal
Understanding the impact of senescence on disease is limited by the lack of tools to lineage label senescent cells. In a recent Cell issue, Zhao et al. create mouse models to genetically manipulate and trace p16+ cells, identifying contrasting roles for senescent macrophages and endothelial cells (ECs) in liver fibrosis.
140